In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Nkarta (NKTX – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $10.49.
Willey covers the Healthcare sector, focusing on stocks such as Exelixis, Geron, and Incyte. According to TipRanks, Willey has an average return of 9.1% and a 42.52% success rate on recommended stocks.
Nkarta has an analyst consensus of Strong Buy, with a price target consensus of $20.50, a 95.42% upside from current levels. In a report released yesterday, H.C. Wainwright also assigned a Buy rating to the stock with a $22.00 price target.
The company has a one-year high of $16.24 and a one-year low of $1.28. Currently, Nkarta has an average volume of 2.09M.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NKTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nkarta (NKTX) Company Description:
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.
